mifepristone has been researched along with Embryopathies in 8 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (12.50) | 18.2507 |
2000's | 5 (62.50) | 29.6817 |
2010's | 1 (12.50) | 24.3611 |
2020's | 1 (12.50) | 2.80 |
Authors | Studies |
---|---|
Barker, E; Latta, K; Laursen, L; Testani, E; York, SL | 1 |
Abreu, P; Alfirevic, Z; Navaratnam, K; Sharp, A | 1 |
Ford, SM; Lim, K; Scherf, C; Willmott, FJ | 1 |
Creemers, JW; Ebbers, S; Lotgering, FK | 1 |
Liggitt, D; Nelson, AM; Ware, CB | 1 |
Bruinse, HW; Christiaens, GC; De Heus, R; Graziosi, GC; Mol, BW | 1 |
Heydanus, R; Papatsonis, DN; Verhulsdonk, MT | 1 |
Fletcher, JC | 1 |
1 review(s) available for mifepristone and Embryopathies
Article | Year |
---|---|
Rupture of uterus in the first trimester during medical termination of pregnancy for exomphalos using mifepristone/misoprostol.
Topics: Abdominal Pain; Abortifacient Agents, Nonsteroidal; Abortion, Therapeutic; Administration, Intravaginal; Administration, Oral; Adult; Drug Therapy, Combination; Female; Fetal Diseases; Hernia, Umbilical; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, First; Ultrasonography; Uterine Rupture | 2008 |
7 other study(ies) available for mifepristone and Embryopathies
Article | Year |
---|---|
Complications of second-trimester medical termination of pregnancy for fetal anomalies compared with intrauterine fetal demise.
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Adult; Female; Fetal Death; Fetal Diseases; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies; Stillbirth | 2023 |
Short versus Standard Mifepristone and Misoprostol Regimen for Second- and Third-Trimester Termination of Pregnancy for Fetal Anomaly.
Topics: Abortifacient Agents; Abortion, Induced; Adult; Female; Fetal Diseases; Humans; Mifepristone; Misoprostol; Pregnancy; Retrospective Studies | 2016 |
[Termination of pregnancy in the 2nd trimester: mifepriston/misoprostol preferable to sulprostone].
Topics: Abortifacient Agents; Abortion, Induced; Adult; Cohort Studies; Dinoprostone; Female; Fetal Diseases; Humans; Middle Aged; Mifepristone; Misoprostol; Parity; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Young Adult | 2009 |
Late gestation modulation of fetal glucocorticoid effects requires the receptor for leukemia inhibitory factor: an observational study.
Topics: Abnormalities, Multiple; Adrenalectomy; Adrenocorticotropic Hormone; Animals; Bone Diseases, Metabolic; Corticosterone; Female; Fetal Diseases; Fetus; Genes, Lethal; Gestational Age; Homeostasis; Hormone Antagonists; Hypothalamo-Hypophyseal System; Interleukin-6; Leukemia Inhibitory Factor; Leukemia Inhibitory Factor Receptor alpha Subunit; Male; Mice; Mice, Inbred C57BL; Mice, Knockout; Mifepristone; Muscle, Skeletal; Neuroglia; Neuroimmunomodulation; Pituitary-Adrenal System; Pregnancy; Proteins; Receptors, Cytokine; Receptors, Glucocorticoid; Receptors, OSM-LIF; Specific Pathogen-Free Organisms; Spinal Cord | 2003 |
Medical management for termination of second and third trimester pregnancies: a comparison of strategies.
Topics: Abortifacient Agents; Abortion, Induced; Dinoprostone; Female; Fetal Death; Fetal Diseases; Humans; Mifepristone; Misoprostol; Pregnancy; Pregnancy Trimester, Second; Pregnancy Trimester, Third; Retrospective Studies; Treatment Outcome | 2004 |
[Results of pregnancy termination for foetal congenital or chromosomal disorders or intrauterine foetal death by oral mifepristone and/or intravaginal misoprostol; results of a retrospective study].
Topics: Abortifacient Agents, Nonsteroidal; Abortion, Induced; Administration, Intravaginal; Administration, Oral; Adult; Female; Fetal Death; Fetal Diseases; Humans; Mifepristone; Misoprostol; Parity; Pregnancy; Pregnancy Trimester, Second; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome | 2007 |
Abortion politics, science, and research ethics: take down the wall of separation.
Topics: Aborted Fetus; Abortion, Induced; Advisory Committees; Altruism; Beneficence; Biomedical Research; Complicity; Embryo, Mammalian; Ethics; Federal Government; Fertilization in Vitro; Fetal Diseases; Fetal Research; Fetal Tissue Transplantation; Fetus; Financial Support; Genetic Therapy; Government; Government Regulation; Guidelines as Topic; Humans; Mifepristone; Morals; Motivation; National Institutes of Health (U.S.); Pharmaceutical Preparations; Policy Making; Pregnancy; Pregnant Women; Public Policy; Research; Risk; Risk Assessment; Social Control, Formal; Social Justice; Stress, Psychological; United States; United States Dept. of Health and Human Services | 1992 |